Isis Pharmaceuticals (NASDAQ:ISIS) is one of today's notable stocks in decline, down 1.3% to $16.78. The Dow is up 0.5% to 14,528 and the S&P is currently up 0.5% to 1,559.
In the past 52 weeks, Isis Pharmaceuticals share prices have been bracketed by a low of $6.25 and a high of $19.53 and are now at $16.78, 168% above that low price. Over the last five market days, the 200-day moving average (MA) has gone up 0.9% while the 50-day MA has advanced 2.0%.
Isis Pharmaceuticals, Inc. discovers and develops novel human therapeutic compounds. The company currently has various compounds in clinical trials for a variety of diseases such as Crohn's disease, psoriasis, asthma, and cancer. Isis' broad medical chemistry and biology research programs support efforts in both antisense and small molecule drug delivery.
Isis Pharmaceuticals (NASDAQ:ISIS) defies analysts with a current price ($16.78) 18.6% above its average consensus price target of $13.67. The stock should find initial support at its 50-day moving average (MA) of $15.27 and further support at its 200-day MA of $12.54.